Palvella Therapeutics, Inc.
NASDAQ: PVLA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Wesley H. Kaupinen
- Employees
- 14
- Headquarters
- Wayne, United States
- IPO year
- 2015
- Market cap
- $1.5B
- Website
- https://palvellatx.com
Loading PVLA…
Loading profile data…Frequently asked questions about PVLA
What does Palvella Therapeutics, Inc. (PVLA) do?
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is cur...
Where does PVLA trade?
Palvella Therapeutics, Inc. (PVLA) trades on the NASDAQ Global Market.
What sector is PVLA in?
Palvella Therapeutics, Inc. (PVLA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Palvella Therapeutics, Inc.?
Wesley H. Kaupinen is the chief executive officer of Palvella Therapeutics, Inc. (PVLA).
Where is Palvella Therapeutics, Inc. headquartered?
Palvella Therapeutics, Inc. is headquartered in United States.
Does PVLA pay a dividend?
Palvella Therapeutics, Inc. (PVLA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PVLA go public?
Palvella Therapeutics, Inc. (PVLA) completed its initial public offering in 2015.